Replimune Group, Inc. REPL
We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer.
Oncolytic immunotherapy is an emerging drug class. Oncolytic immunotherapy exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. Our product candidates incorporate multiple mechanisms into a practical "off-the-shelf" approach that is intended to maximize the immune response against a patient's cancer and to offer significant advantages over other approaches to inducing anti-tumor immunity. We believe that the bundling of multiple approaches for the treatment of cancer into single therapies will increase clinical efficacy and simplify the development path of our product candidates, while also improving patient outcomes.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $221.2M | $189.4M | $175.0M | $126.5M | $79.5M | $56.8M | $38.8M | $22.2M | $13.5M | $6.9M |
| SG&A | $98.7M | $72.2M | $59.8M | $50.6M | $38.8M | $23.2M | $17.4M | $8.8M | $5.7M | $2.7M |
| Total operating expenses | $319.9M | $261.6M | $234.8M | $177.1M | $118.3M | $80.0M | $56.2M | $30.9M | $19.2M | $9.6M |
| Operating income | -$319.9M | -$261.6M | -$234.8M | -$177.1M | -$118.3M | -$80.0M | -$56.2M | -$30.9M | -$19.2M | -$9.6M |
| Pre-tax income | -$314.5M | -$246.8M | -$215.4M | -$174.0M | -$118.0M | -$80.9M | -$52.6M | -$30.8M | -$19.7M | -$7.7M |
| Income tax | $551.0K | $468.0K | $408.0K | $288.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$313.9M | -$247.3M | -$215.8M | -$174.3M | -$118.0M | -$80.9M | -$52.6M | -$30.8M | -$19.7M | -$7.7M |
| EPS, basic | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 | -1.75 | — | — | — | — |
| EPS, diluted | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -3.96 | -1.55 |
| Shares, diluted (wtd. avg.) | 92.8M | 80.6M | 66.6M | 58.2M | 52.2M | 46.2M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $209.0M | $111.1M | $76.2M | $148.2M | $107.6M | $184.2M | $61.1M | $26.9M | $17.7M | $20.7M |
| Short-term investments | $59.9M | $372.7M | $346.2M | $436.8M | $289.7M | $293.8M | $109.1M | $109.1M | $44.0M | — |
| Total current assets | $279.1M | $495.9M | $433.7M | $592.6M | $404.0M | $483.7M | $174.3M | $141.0M | $64.7M | — |
| Property, plant and equipment | $13.0M | $13.7M | $10.5M | $7.5M | $7.9M | $7.4M | $6.9M | $12.2M | $370.0K | — |
| Total assets | $332.4M | $551.3M | $487.7M | $646.6M | $461.2M | $543.1M | $234.1M | $154.3M | $65.2M | — |
| Accounts payable | $6.7M | $12.5M | $2.6M | $5.4M | $3.7M | $2.4M | $3.4M | $7.1M | $2.0M | — |
| Total current liabilities | $58.2M | $62.4M | $40.4M | $33.8M | $20.8M | $14.5M | $11.9M | $9.9M | $5.2M | — |
| Long-term debt | $83.3M | $46.4M | $44.8M | $28.6M | $0 | — | $9.8M | — | — | — |
| Total liabilities | $166.2M | $135.5M | $113.2M | $91.3M | $50.0M | $44.4M | $50.4M | $16.5M | $6.9M | — |
| Retained earnings | -$1.26B | -$948.6M | -$701.3M | -$485.5M | -$311.2M | -$193.2M | -$112.3M | -$59.8M | -$28.9M | — |
| Total equity | $166.2M | $415.8M | $374.5M | $555.3M | $411.2M | $498.7M | $183.7M | $137.9M | -$28.1M | -$11.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$280.3M | -$192.2M | -$185.5M | -$128.1M | -$82.2M | -$61.4M | -$60.6M | -$25.4M | -$16.0M | -$7.1M |
| Depreciation and amortisation | $3.3M | $3.5M | $2.7M | $2.4M | $2.1M | $1.7M | $533.0K | $148.0K | $109.0K | $122.0K |
| Stock-based compensation | $32.3M | $35.0M | $34.1M | $28.1M | $24.3M | $11.8M | $7.7M | $2.7M | $812.0K | $208.0K |
| Capital expenditure | $4.2M | $6.7M | $5.7M | $2.3M | $2.3M | $2.4M | $6.5M | $2.6M | $136.0K | $238.0K |
| Investing cash flow | $310.8M | -$23.8M | $97.2M | -$142.5M | -$1.8M | -$188.8M | -$5.2M | -$65.9M | -$44.0M | -$238.0K |
| Financing cash flow | $66.3M | $252.4M | $16.3M | $311.3M | $6.6M | $372.5M | $100.2M | $101.4M | $54.8M | $15.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-087650.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$7.7M | -$19.7M | -$30.8M | -$52.6M | -$80.9M | -$118.0M | -$174.3M | -$215.8M | -$247.3M | -$313.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |